Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore which altcoins have strong teams and performance, highlighting projects with solid development and momentum. Learn how team credibility aligns with price trends and long-term potential.
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A once-overlooked dividend ETF is delivering double-digit gains this year, signaling a shift from megacap leadership ...
When vertex stock rising today captures headlines, investors should look beyond the flash. This guide explains the wh...
A $1,100 facebook rental looked like a dream in a walkable neighborhood. This guide explains how these scams work, re...
U.S. households show mounting stress as debt payments rise, savings shrink, and spending cools. Five indicators point...
A broad sell-off hit four key quantum names after a sharp Monday rally, with profit-taking and sentiment shifts weigh...
A hidden property tax rule in Charleston can swing long-term retirement funds. The 4% vs 6% assessment gap may add up...
XRP is testing the $1 threshold as ETF inflows stall after a weeks-long surge. This price analysis evaluates implicat...
Mexico advances a phased plan to cut the standard workweek from 48 to 40 hours by 2030, with a gradual two-hour reduc...
Stocks are riding high on robust earnings, but a looming bear market appears increasingly likely as rate paths and st...
Bitcoin Japan, which holds no BTC, launches a $60 million fundraising round led by EVO Fund to acquire its first bitc...
A high-profile kidnapping tied to crypto ransom ends in an arrest abroad, underscoring risks for the crypto ecosystem...